Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results Accessibility StatementSkip Navigation LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult- to-treat bacterial infections, today announced financial results for its fo ...